Based on the ODYSSEY Outcomes Trial, specifically the low LDL-C levels achieved without adverse consequences, what target level of LDL-C do you recommend in medically managed patients with moderate-to-high risk features of ASCVD?

Based on the ODYSSEY Outcomes Trial, specifically the low LDL-C levels achieved without adverse consequences, what target level of LDL-C do you recommend in medically managed patients with moderate-to-high risk features of ASCVD?

CLICK HERE FOR CME CREDIT

http://cmr.2.2.broadcastmed.net/videos/from-a-medical-cardiologist-s-perspective-which-patient-subgroups-in-your-practice-do-you-feel-represent-ideal-candidates-for-deployment-of-pcsk9-inhibitors-to-lower-ldl-c-levels-based-on-the-results-of-the-odyssey-outcomes-and-fourier-t/flushcache/1/showdraft/1

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical and Preventive Cardiologist's Perspective

Presenter

Robert Rosenson, MD

Robert Rosenson, MD

Professor of Medicine (Cardiology) Mount Sinai Icahn School of Medicine Director, Cardiometabolics Unit Mount Sinai Heart Institute New York, NY